Consolidated Statement Of Comprehensive Income

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7328356

Concept 2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
Consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
2,466,000,000 JPY
7,545,000,000 JPY
2,466,000,000 JPY
2,466,000,000 JPY
2,466,000,000 JPY
591,000,000 JPY
591,000,000 JPY
591,000,000 JPY
591,000,000 JPY
4,238,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
202,000,000 JPY
1,371,000,000 JPY
Remeasurements of defined benefit plans, net of tax
362,000,000 JPY
144,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
16,000,000 JPY
229,000,000 JPY
Other comprehensive income
581,000,000 JPY
1,745,000,000 JPY
Comprehensive income
8,127,000,000 JPY
5,983,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
8,127,000,000 JPY
5,983,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.